CRISPR Therapeutics AG rose 6.70% before a late-breaking CTX310 presentation. The stock closed Tuesday at $60.90. Volume reached 2.08 million shares.
Investors paid for clinical optionality before the August 28 durability update.
Daily closes, Aug. 17–25, 2026. The latest move recaptured the prior week's high.
The valuation test shifts from anticipation to durability.
Citizens kept an $80 target. CRSP closed 6.70% higher on 1.24× average volume.
Late-breaking ESC presentation. The scheduled 10:30 EDT session covers Phase 1a CTX310 durability.
Management expects another CTX310 update as Phase 1b evaluates additional patients and dose selection.
Can one-time ANGPTL3 editing preserve lipid reductions without new safety signals? Durable effects would strengthen the cardiovascular-platform case. Short-lived effects would weaken it.
Mean reductions at the highest tested dose in initial Phase 1 data; investigational treatment, not an approved product.
Maximum individual reductions were 89%, 84% and 87%, respectively. Initial analysis covered 15 participants with average follow-up of at least 60 days. No treatment-related serious adverse events or grade 3-or-higher liver-transaminase changes were reported.
Reported for the quarter ended June 30, 2026.
The 26-quarter figure is a mechanical ratio, not management guidance. Clinical spending, milestones and working capital will change the actual runway.
Targets available Aug. 25, 2026; upside or downside versus the $60.90 close.
| Reference | Target | Implied move |
|---|---|---|
| Citizens | $80.00 | +31.4% |
| S&P Global average | $87.56 | +43.8% |
| S&P Global median | $80.00 | +31.4% |
| S&P Global low | $44.00 | −27.8% |
BUY S&P Global consensus across 22 analysts. Targets are opinions, not forecasts.
Vertex leads commercialization; economics are shared with CRISPR Therapeutics.
Vertex and CRISPR Therapeutics share CASGEVY profits and costs 60%/40%. The approved therapy provides commercial validation, but CTX310 has a different delivery method, target and risk profile.
The stock move came before detailed durability data.
| Cash + marketable securities | $2.364B |
| Cash as share of market cap | 40.5% |
| Q2 revenue | $10.2M |
| Q2 R&D expense | $67.2M |
| Q2 net loss | $91.2M |
| CASGEVY Q2 global revenue | $76M |
| Firm | Latest action | Rating | Target | Implied return |
|---|---|---|---|---|
| Citizens | Aug. 25 | Market Outperform | $80 | +32.5% |
| Goldman Sachs | Aug. 10 | Hold | $55 | −8.9% |
| Bank of America | Aug. 5 | Buy | $82 | +35.8% |
| Morgan Stanley | Aug. 4 | Hold | $60 | −0.6% |
| Piper Sandler | Aug. 4 | Buy | $110 | +82.2% |
A durable ANGPTL3 response could add an in-vivo cardiovascular franchise beside CASGEVY. Tuesday's move capitalized that possibility before the data.
CTX310 is early-stage. Small cohorts, safety findings or weaker durability could erase the move. Clinical value remains distinct from commercial value.
$319 million gained versus $2.364 billion of liquidity. The stock's one-day market-value increase equals roughly 13.5% of reported cash and securities. Citizens' $80 target adds another $1.90 billion of implied equity value from the midday base. The August 28 data therefore tests whether investors will assign meaningful value to CTX310 before later-stage evidence.
Sources: CRISPR Therapeutics Q2 2026 business update; Google Finance; Citizens research note reported by Investing.com. Calculations may differ slightly because market capitalization and shares outstanding are rounded.
